

ASX Announcement

1 March 2024

BCAL TO HOST INVESTOR WEBCAST

Breast cancer screening and diagnostic company BCAL Diagnostics Limited (ASX:BDX, 'BCAL' or the 'Company') is pleased to announce it will be hosting an investor webinar on Wednesday 6th March 2024 at 11am AEDT (Sydney/Melbourne).

The webcast will be hosted by BCAL's Executive Chair, Jayne Shaw, Chief Executive Officer, John Hurrell and Chief Operating Officer, Shane Ryan, who will provide an overview of operational and clinical highlights from H1 FY24, following the release of the Appendix 4D last week (Ref ASX announcement 21 February 2024) as well as an outline of the Company's growth strategy in preparation for the commercial launch of BREASTEST™ in late 2024.

Webcast Details

Date:	Wednesday 6 th March 2024
Time:	11:00am AEDT (Sydney/Melbourne)
Registration:	https://us02web.zoom.us/webinar/register/WN_hOJ-0owaQq2Yt6fhgxHwiQ

Shareholders are encouraged to send questions ahead of time to we-aubcaldiagnostics@we-worldwide.com. For those unable to join, a recording of the call will be available on the company website shortly following completion.

ENDS**For further information:****Jayne Shaw**

Executive Chair
Jshaw@bcaldiagnostics.com

Guy Robertson

Chief Financial Officer
grobertson@bcaldiagnostics.com

About BCAL Diagnostics

BCAL Diagnostics Limited is an Australian screening and diagnostic company committed to the early, accurate diagnosis of breast cancer, and therefore early intervention and improved outcomes for women. Over the past decade BCAL has developed a non-invasive blood test for the detection of breast cancer, with results to date demonstrating 90% sensitivity and 85.5% specificity. The test is initially designed to complement current imaging technologies, such as the mammogram, with the aim of becoming a monitoring and screening tool suitable for women of all ages and backgrounds in any location. With more than two million new cases of breast cancer diagnosed globally each year, a substantial opportunity exists for BCAL to improve patient outcomes.

Founded in 2010, BCAL is headquartered in Sydney and listed on the Australian Securities Exchange (ASX: BDX). For more information: <https://www.bcaldiagnostics.com/>